Teva Pharmaceuticals

1527 articles with Teva Pharmaceuticals

• TEVA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Teva Pharmaceutical Industries Limited To Contact The Firm

  5/13/2019

  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Teva Pharmaceuticals Industries Limited.

• 

  Sandoz, Teva Vow to Fight Price-Fixing Allegations

  5/13/2019

  The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
• 

  Legal Decision Could Open the Doors for Truvada Generic Competition One Year Early, Gilead Says

  5/13/2019

  Gilead's Truvada is expected to lose patent protection in 2021, but a recent court decision in Europe could change that.

• Teva Announces the Launch of a Generic Version of Delzicol® (mesalamine) Delayed-Release Capsules in the United States

  5/10/2019

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of Delzicol®1 (mesalamine) delayed-release capsules, 400 mg, in the U.S.

• Teva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United States

  5/9/2019

  Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Tarceva®1 tablets, 100 and 150 mg, in the U.S.

• Teva to Present New Long-Term Data on Efficacy and Safety of Fremanezumab at 2019 American Academy of Neurology Annual Meeting

  5/3/2019

  Findings describe the efficacy and safety results of clinical trials of fremanezumab through 12 months of treatment in patients with chronic and episodic migraine

• Teva Reports First Quarter 2019 Financial Results

  5/2/2019

  Spend base reduction of $2.5 billion since initiation of the restructuring plan in 2018; on-track to achieve $3.0 billion by the end of 2019

• Teva Announces Launch of a Generic Version of Letairis® (ambrisentan) Tablets in the United States

  5/1/2019

  Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Letairis®1 Tablets, 5 mg and 10 mg, in the U.S.

• Teva to Present New Central Nervous System Portfolio Data at 71st Annual Meeting of the American Academy of Neurology

  5/1/2019

  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Company will present data at the 71st Annual Meeting of the American Academy of Neurology (AAN) in Philadelphia from May 4-10, 2019

• 

  Teva Recalls More Tainted Blood Pressure Drugs

  4/30/2019

  Teva Pharmaceuticals recalled 35 lots of bulk Losartan Potassium after a known carcinogen was discovered in the active pharmaceutical ingredient.

• Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply

  4/25/2019

  Teva Pharmaceuticals USA, Inc. has initiated a voluntary recall in the United States, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength).

• 

  Teva Pharma Halts Development of Cluster Headache Drug

  4/23/2019

  Israel-based Teva Pharmaceuticals announced that it is halting the clinical development of fremanezumab (Ajovy) for cluster headaches. They based the decision on a pre-specified futility analysis of a Phase III clinical trial in episodic cluster headaches.
• 

  FDA Approves Teva’s Generic Naloxone Opioid Overdose Drug

  4/22/2019

  The FDA said the approval of Teva’s product is the first generic naloxone nasal spray for use in a community setting by individuals without medical training.

• Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility

  4/10/2019

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new $2.3 billion unsecured revolving credit facility, which replaces its existing $3.0 billion credit facility.

• xCella Announces New Antibody Development Program

  4/9/2019

  xCella Biosciences announced a new antibody discovery research collaboration with Teva Pharmaceuticals Australia Pty Ltd. xCella will use its xPlorationTM single cell screening platform to identify rare antibodies against an undisclosed target of interest to Teva.

• Teva to Host Conference Call to Discuss First Quarter 2019 Financial Results at 8 a.m. ET on May 2, 2019

  4/8/2019

  Teva Pharmaceutical Industries Ltd. announced that it will issue a press release on its first quarter 2019 financial results on Thursday, May 2, 2019 at 7:00 a.m. ET.

• Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults

  4/1/2019

  In clinical trials, many patients on AJOVY experienced significant reductions of at least 50% in the number of monthly migraine days with reduction observed as early as week one

• Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

  4/1/2019

  Teva Pharmaceutical Industries Ltd. announced that a three-member panel of the European Patent Office’s Opposition Division upheld patent EP 2 949 335 covering Teva’s COPAXONE® 40mg product in Europe.

• Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United States

  3/22/2019

  Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S.

• Teva Selects Genedata Biologics to Support Next-generation Biopharmaceuticals R&D

  3/21/2019

  Genedata Biologics® streamlines Teva’s R&D workflows and increases operational efficiency